CD1d-knockout mice allowed faster subcutaneous development of B16F10-Nex2 tumors than WT mice. Wild type mice (--) and CD1d-knockout mice (----) were injected subcutaneously with 5 × 104 viable B16F10-Nex 2 cells. Animal survival was registered for 70 days. Mice were sacrificed when tumors reached 3,000 mm3. Results are representative of 4 independent experiments. p < 0.001.